Genor Biopharma Holdings (HKG:6998) has decided to postpone its extraordinary general meeting to Feb. 19 from Feb. 13, a Tuesday bourse filing said.
The delay was attributed to the company requiring additional time to determine certain information related to the company's proposal to change its auditor from PricewaterhouseCoopers to Ernst & Young.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.